Regulation of differentiation of the BC3H1 muscle cell line through cAMP-dependent and -independent pathways.
Serum mitogens, fibroblast growth factor (FGF), and type beta transforming growth factor (TGF-beta) suppress differentiation of the mouse muscle cell line BC3H1; however, the signal transduction pathways whereby these growth factors exert their effects on this system are unknown. The goal of this study was to determine whether the program for differentiation of BC3H1 cells was susceptible to negative regulation by signaling pathways involving cAMP or protein kinase C and whether these intracellular effectors participate in the mechanism by which growth factors prevent establishment of the myogenic phenotype. Exposure of BC3H1 cells to dibutyryl cAMP, 8-bromo-cAMP, or compounds that stimulate adenylate cyclase, i.e. forskolin, prostaglandin E1, and cholera toxin, prevented up-regulation of muscle-specific gene products following growth arrest in mitogen-deficient medium. Conversely, addition of cAMP to differentiated BC3H1 myocytes caused down-regulation of muscle-specific mRNAs. In contrast to the ability of cAMP to block differentiation, chronic exposure to O-tetradecanoylphorbol-13-acetate, the potent activator of protein kinase C, exhibited no apparent effects on expression of muscle-specific gene products. The proto-oncogenes c-myc and c-fos were up-regulated rapidly by cAMP in a manner similar to that observed previously by serum, FGF, and TGF-beta. However, these growth factors failed to increase intracellular cAMP levels, and they did not induce ornithine decarboxylase, which was subject to positive regulation by cAMP and O-tetradecanoyl-13-acetate. Together, these data indicate that differentiation of BC3H1 cells is subject to negative regulation through a cAMP-dependent pathway and that serum mitogens, FGF, and TGF-beta inhibit differentiation through a mechanism independent of cAMP or protein kinase C.
Hu
J S
JS
Department of Biochemistry and Molecular Biology, University of Texas, M. D. Anderson Cancer Center, Houston 77030.
Olson
E N
EN
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D005576:Colforsin / Q000494:pharmacology; D003402:Creatine Kinase / Q000378:metabolism; D000242:Cyclic AMP / Q000502:physiology*; D005346:Fibroblast Growth Factors / Q000494:pharmacology; D007700:Kinetics; D051379:Mice; D009132:Muscles / Q000166:cytology*; D009955:Ornithine Decarboxylase / Q000096:biosynthesis; D011519:Proto-Oncogenes / Q000187:drug effects; D012313:RNA / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D011950:Receptors, Cholinergic / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D015291:Transforming Growth Factors / Q000494:pharmacology; D014336:Troponin / Q000235:genetics; D020107:Troponin T
D012333:RNA, Messenger; D011950:Receptors, Cholinergic; D014336:Troponin; D020107:Troponin T; D005576:Colforsin; D005346:Fibroblast Growth Factors; D012313:RNA; D003994:Bucladesine; D015291:Transforming Growth Factors; D000242:Cyclic AMP; D003402:Creatine Kinase; D009955:Ornithine Decarboxylase; D000527:Alprostadil; D013755:Tetradecanoylphorbol Acetate; D015056:1-Methyl-3-isobutylxanthine